

February 21, 2022



## Astrocyte Pharmaceuticals 2022 Q1 Investor Update

(Q4 2021 Financials)

To all Astrocyte Pharmaceuticals Shareholders,

The Astrocyte team continues to push steadily ahead as we plan for the start of human clinical testing of AST-004. There is, however, a delay to the start of the Phase 1 study. In January we heard back from Hungary's Regulatory Authority (OGYEI) on the two-part review of our Phase 1 Clinical Trial Application. While the country's Central Ethics Committee (CEC) approved the planned protocol, the country's National Institute of Pharmacy and Nutrition (OGYÉI) rejected the application. The FDA, EMA and major regulatory authorities across the globe have worked with the pharmaceutical industry to develop the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use ([ICH](#)) which harmonizes the guidelines across all countries. Unfortunately, there is a discrepancy between the U.S. and Europe in one particular aspect relating to short, acute treatment clinical studies. We are amending the planned human study protocol to better address this discrepancy and will submit the updated Clinical Trial Application (CTA) in the upcoming week. Approval of the new CTA, which we believe is likely but not guaranteed, would enable the Phase 1 study to start in Q2. As a precaution, the Astrocyte team is also reviewing options to start the Phase 1 soon in the U.S. or another country.



In December, we [announced that Christine Gallagher](#) has joined the Astrocyte's Board of Directors. Christine has over 30 years of experience as an investment banker focused on the life sciences industry. She is currently Managing Director, Equity Capital Markets at Truist Securities (formerly SunTrust Robinson Humphrey) where she is directly responsible for leading the planning, structuring and execution of equity capital raises for public and private companies. Ms. Gallagher has been an advisor to numerous boards and management teams on a wide range

of corporate finance solutions and her healthcare investment banking experience includes the execution of over 150 mergers and acquisitions (M&A), advisory and financing transactions raising over \$35 billion of capital and advisory work valued at over \$20 billion. Christine brings to Astrocyte tremendous experience across an extensive range of biopharmaceutical companies, growth strategies and financing approaches, and her guidance will be invaluable as we assess growth options in 2022 and beyond.

Astrocyte's BOD has reviewed and approved the Company's budget for 2022. Assuming start of the clinical trial as planned in Q2, this budget would provide for 6 months+ of cash runway beyond the completion of the Phase 1 study in order to provide flexibility and options when deciding on how best to advance AST-004 into Phase 2 clinical studies, and to maximize shareholder returns. The confidential 2022 budget and the standard quarterly financial statements for Q4 2021 are available upon request.

Finally, each August Astrocyte hosts a confidential Annual Shareholder Science Update meeting. We have selected Thursday, August 11<sup>th</sup> at 10:00am EDT for this meeting and will host it in person in Kendall Square, Cambridge, MA as well as broadcast it via Zoom. Please put a hold in your calendars.

We thank all of you for your continued support of Astrocyte and our promising AST-004 program and we look forward to our next update regarding the start of human trials.

Sincerely,



William S. Korinek  
CEO, Astrocyte Pharmaceuticals Inc.

---

[Visit Astrocyte Website](#)

Copyright © 2022 Astrocyte Pharmaceuticals Inc., All rights reserved.

You are receiving this email as a Seed or Series A Preferred shareholder in Astrocyte Pharmaceuticals Inc. We are providing regular updates to our investors. If you are not the intended recipient, please immediately delete this email and any attachments.